|Table of Contents|

Application value of detection of serum pepsinogen,gastrin-17 and Helicobacter pylori in screening gastric cancer in physical examination population

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2023 16
Page:
3041-3045
Research Field:
Publishing date:

Info

Title:
Application value of detection of serum pepsinogen,gastrin-17 and Helicobacter pylori in screening gastric cancer in physical examination population
Author(s):
LI Mei; XU Jia; LIU Yuping
Health Management Center,Sichuan Academy of Medical Sciences·Sichuan Provincial People's Hospital (Affiliated Hospital of University of Electronic Science and Technology of China),Sichuan Chengdu 610072,China.
Keywords:
gastric tumor; pepsinogen; gastrin-17; Helicobacter pylori infection; physical examination population
PACS:
R735.2
DOI:
10.3969/j.issn.1672-4992.2023.16.018
Abstract:
Objective:To explore the application value of serum pepsinogen Ⅰ(PG Ⅰ),PG Ⅱ,PG Ⅰ/PG Ⅱ,gastrin-17 (G-17) and Helicobacter pylori (H.pylori) serological screening indexes in gastric cancer screening of physical examination population.Methods:A total of 25 387 physical examination population who had undergone serum PG,G-17 detection and 13C urea breathing test(13C-UBT) in the health management center of our hospital from January 2020 to December 2021 were retrospectively included as the study subjects.PG(+),G-17(+),H.pylori(+) randomly meeting 2 or more items or PG and G-17 abnormal alone were defined as high-risk group.Patients in high-risk group were examined by gastroscope and further pathological biopsy.According to pathological diagnosis,they were divided into precancerous conditions,precancerous lesions,early gastric cancer,advanced gastric cancer and control group (normal gastric mucosa group).The relationship between PG,G-17,H.pylori and the occurrence of various pathological changes of gastric mucosa and the value of screening gastric cancer were analyzed.Results:There were 7 592 cases (29.9%) in the high-risk group of serological screening.The composition of men,H.pylori infection rate and average age in the high-risk group were higher than those in the low-risk group,and the median levels of PG Ⅰ,PG Ⅰ/PG Ⅱ and G-17 in the high-risk group were lower than those in the low-risk group,with significant differences (all P＜0.05).The levels of PG Ⅰ and G-17 in the H.pylori positive group were higher than those in the negative group,while the ratio of PG Ⅰ/PG Ⅱ was lower than that in the negative group (P＜0.05).A total of 1 511 cases were examined by endoscopy.832 cases of precancerous status,126 cases of precancerous lesions,19 cases of early gastric cancer,and 10 cases of advanced gastric cancer were detected.The detection rate of gastric cancer was 0.11% (29/25 387),and the early rate was 65.5% (19/29).The levels of PG Ⅰ and PG Ⅰ/PG Ⅱ decreased with the increase of gastric mucosal lesion,and the H.pylori infection rate increased with the increase of gastric mucosal lesion,and the difference was statistically significant (P＜0.05).The combined detection of the three methods had significantly higher diagnostic value for gastric cancer and precancerous lesions (AUC=0.805,95%CI:0.799~0.841).Conclusion:The H.pylori positive rate of patients with different gastric mucosal lesions increased with the severity of the lesions,while the levels of PG Ⅰ and PG Ⅰ/PG Ⅱ decreased with the severity of the lesions.Serological screening is an active exploration of early diagnosis and treatment of cancer based on physical examination population.

References:

[1] MACHLOWSKA J,BAJ J,SITARZ M,et al.Gastric cancer:epidemiology,risk factors,classification,genomic characteristics and treatment strategies［J］.Int J Mol Sci,2020,21(11):4012.
[2] LYONS K,LE LC,PHAM YT,et al.Gastric cancer:epidemiology,biology,and prevention:a mini review［J］.Eur J Cancer Prev,2019,28(5):397-412.
[3] SUNG H,FERLAY J,SIEGEL RL,et al.Global cancer statistics 2020:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries［J］.CA Cancer J Clin,2021,71(3):209-249.
[4] 成姝雯，董婷，曾晶，等.2015年四川省肿瘤登记地区恶性肿瘤发病和死亡情况分析［J］.实用肿瘤学杂志，2020,34(4):304-308. CHENG SW,DONG T,ZENG J,et al.Analysis of cancer incidence and mortality in registration areas of Sichuan,2015［J］.Practical Oncology Journal,2020,34(4):304-308.
[5] 国家消化系统疾病临床医学研究中心，中华医学会消化内镜学分会，中华医学会健康管理学分会，等.中国早期胃癌筛查流程专家共识意见(草案)(2017年,上海)［J］.中华消化杂志，2018,38(2):87-92. National Clinical Medical Research Center for Digestive System Diseases,Digestive Endoscopy Branch of Chinese Medical Association,Health Management Branch of Chinese Medical Association,et al.Expert consensus on the screening process of early gastric cancer in China (draft) (Shanghai,2017)［J］.Clin J Dig,2018,38(2):87-92.
[6] KAKEJI Y,ISHIKAWA T,SUZUKI S,et al.A retrospective 5-year survival analysis of surgically resected gastric cancer cases from the Japanese Gastric Cancer Association nationwide registry (2001-2013)［J］.Gastric Cancer,2022,25(6):1082-1093.
[7] KAKINUMA D,ARAI H,YASUDA T,et al.Treatment of gastric cancer in Japan［J］.J Nippon Med Sch,2021,88(3):156-162.
[8] 中华医学会肿瘤学分会,中华医学会杂志社.中华医学会胃癌临床诊疗指南(2021版)［J］.中华医学杂志，2022,102(16) :1169-1189. Oncology Branch of Chinese Medical Association,Journal of Chinese Medical Association.Chinese Medical Association guidelines for clinical diagnosis and treatment of gastric cancer (2021 edition)［J］.Natl Med J China,2022,102(16) :1169-1189.
[9] GANTUYA B,OYUNTSETSEG K,BOLOR D,et al.Evaluation of serum markers for gastric cancer and its precursor diseases among high incidence and mortality rate of gastric cancer area［J］.Gastric Cancer,2019,22(1):104-112.
[10] KUMAR S,METZ DC,ELLENBERG S,et al.Risk factors and incidence of gastric cancer after detection of helicobacter pylori infection:a large cohort study［J］.Gastroenterology,2020,158(3):527-536.
[11] LI S,CHUNG DC,MULLEN JT.Screening high-risk populations for esophageal and gastric cancer［J］.J Surg Oncol,2019,120(5):831-846.
[12] SEXTON RE,AL HALLAK MN,DIAB M,et al.Gastric cancer:a comprehensive review of current and future treatment strategies［J］.Cancer Metastasis Rev,2020,39(4):1179-1203.
[13] 贾尚春，徐伟，刘荣，等.2018-2019年安徽省农村居民胃癌筛查检出情况及相关影响因素分析［J］.中国肿瘤，2020,29(7):503-508. JIA SC,XU W,LIU R,et al.Result and related influencing factors of gastric cancer screening for rural residents in Anhui Province,2018-2019［J］.China Cancer,2020,29(7):503-508.
[14] 吴秀贞，覃向向，李毅，等.2012-2018年山东临朐胃癌高发区胃癌早诊率及胃黏膜病变进展规律分析［J］.中华肿瘤防治杂志，2019,26(22):1686-1691,1709. WU XZ,QIN XX,LI Y,et al.Early diagnosis of gastric cancer and progression of gastric lesions 2012-2018 in Linqu,Shandong Province of China［J］.Chinese Journal of Cancer Prevention and Treatment,2019,26(22):1686-1691,1709.
[15] ZHOU X,ZHU H,ZHU C,et al.Helicobacter pylori infection and serum pepsinogen level with the risk of gastric precancerous conditions:a cross-sectional study of high-risk gastric cancer population in China［J］.J Clin Gastroenterol,2021,55(9):778-784.
[16] 李俊，姚保栋，李为希，等.血清幽门螺杆菌抗体、胃蛋白酶原、胃泌素-17 检测对5552名社区胃癌高危人群的筛查研究［J］.中国肿瘤，2019,28(8):629-635. LI J,YAO BD,LI WX,et al.Gastric cancer screening with serum helicobacter pylori antibody,pepsinogen and gastrin-17 among high-risk residents in community［J］.China Cancer,2019,28(8):629-635.
[17] YAMAGUCHI Y,NAGATA Y,HIRATSUKA R,et al.Gastric cancer screening by combined assay for serum anti-helicobacter pylori IgG antibody and serum pepsinogen levels-the ABC method［J］.Digestion,2016,93(1):13-18.
[18] CROWE SE.Helicobacter pylori infection［J］.N Engl J Med,2019,380(12):1158-1165.
[19] IN H,SARKAR S,WARD J,et al.Serum pepsinogen as a biomarker for gastric cancer in the United States:a nested case-control study using the PLCO cancer screening trial data［J］.Cancer Epidemiol Biomarkers Prev,2022,31(7):1426-1432.

Memo

Memo:
国家重点研发计划子课题（编号：2017YFC0113901）;四川省干保委课题（编号：川干研 2017-205）
Last Update: 1900-01-01